Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections
Faura et al. Journal of Neuroinflammation
https://doi.org/10.1186/s12974-021-02177-0
(2021) 18:127
REVIEW
Open Access
Stroke-induced immunosuppression:
implications for the prevention and
prediction of post-stroke infections
Júlia Faura1, Alejandro Bustamante2*, Francesc Miró-Mur3 and Joan Montaner1,4
Abstract
Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune
system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a
shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and
NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes.
The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections,
which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is
the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and
prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early
prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate
enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP,
and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local
immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies
have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain
injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as
inflammation of the bronchoalveolar lavage fluid.
Keywords: Stroke, Immunosuppression, Biomarkers, Inflammation, Infection, Pneumonia
Background
Stroke-induced immunosuppression (SIIS) is a set of processes that lead to a peripheral suppression of the immune
system after the occurrence of stroke. One of the main
and direct consequences of this SIIS is that it makes stroke
patients more susceptible to bacterial infections. Strokeassociated infections (SAIs) represent one of the major
complications post-stroke, which worsens the functional
outcome of patients and increases their mortality rates [1].
Approximately 30% (24–36%) of patients develop
* Correspondence:
2
Stroke Unit, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet,
s/n, 08916 Badalona, Barcelona, Spain
Full list of author information is available at the end of the article
infections after stroke, with pneumonia and urinary tract
infections (UTI) being the most common forms, both having a frequency of 10% [2].
Among these infections, stroke-associated pneumonia
(SAP) is usually the most acute type of SAI and has the
worst impact on functional outcome [3]. It increases
mortality for up to 1 year, prolongs hospital stays, and
worsens the functional outcome at discharge [4]. The
clinical definition of pneumonia after stroke has differed
in many studies in both the terminology and the diagnosis of the complication [5]. To address this issue, the
Pneumonia in Stroke Consensus (PISCES) Group proposed the term SAP, to encompass all terms referring to
lower respiratory tract infections in stroke patients
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
Faura et al. Journal of Neuroinflammation
(2021) 18:127
within the first 7 days after stroke onset [6]. In the same
publication, new diagnostic criteria were proposed based
on the criteria for the definition of healthcare-associated
infection from the Centers for Disease Control and Prevention (CDC) of the United States of America, which
were the most used criteria by that point [7]. However,
SAP assessment is still challenging, especially due to the
limited role of chest radiography. For this, chest computed tomography has been proposed as a complement
to PISCES criteria in the screening of SAP in stroke patients. In a small cohort, thorax high-resolution computed tomography (THRCT) was able to differentiate
between bronchopneumonia and other low respiratory
tract infections in SAP patients, demonstrating a high
accuracy in the diagnosis of SAP [8]. More recently,
Kishore et al. [9] have also addressed this issue, but they
have observed that conventional chest X-rays have limited accuracy for the diagnostic of SAP when compared
with THRCT. Similarly, they found in their work some
discrepancies between PISCES criteria and THRCT. Larger studies, including perhaps serial imaging, are needed
in this field, to validate whether PISCES criteria and
THRCT might be combined for the diagnosis of SAP.
Nowadays, the clinical strategies against SAP are based
on wide-spectrum antibiotics once an infection is diagnosed through clinical criteria, along with prevention by
dysphagia screening in stroke units. Recently, the PISC
ES consortia launched a recommendation for a standardized approach to antibiotic therapy in post-stroke
pneumonia [10]. Nonetheless, early treatment before the
development of clinical signs could prevent the onset of
SAP or ameliorate its consequences. This would have
benefits for patients and saving also a great number of
resources for health care systems [11]. Several clinical
trials have explored this idea through the administration
of prophylactic antibiotics to acute stroke patients. However, the meta-analysis performed by Vermeij et al. [12]
showed that preventive antibiotics neither reduce the
risk of pneumonia nor the risk of death or poor outcome
after stroke. The treatment did reduce the occurrence of
overall infections and UTIs, but did not show any effect
regarding the occurrence of SAP. These results were
translated into recommendations against the routine us (...truncated)